Other Gains and Losses, and Litigation |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Analysis of income and expense [abstract] | |
| Other Gains and Losses, and Litigation | B.17. Other gains and losses, and litigation For the first half of 2025, Other gains and losses, and litigation € 57 million, mainly related to major litigation. That compares with a charge of € 450 million in the first half of 2024, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii. Figures for the 2024 comparative period have been
re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. |